Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

被引：56

作者：

Cha, R

Brown, WJ

Rybak, MJ

机构：

[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48201 USA

[2] Wayne State Univ, Sch Med, Detroit, MI 48201 USA

[3] Wayne State Univ, DMC Univ Labs, Detroit, MI 48201 USA

[4] Wayne State Univ, Detroit Receiving Hosp, Detroit, MI 48201 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 12期

关键词：

D O I：

10.1128/AAC.47.12.3960-3963.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In search of treatment alternatives against vancomycin-resistant S. aureus (VRSA), an in vitro pharmacodynamic model with simulated endocardial vegetations incorporating protein and a high inoculum was used to simulate daptomycin, linezolid, quinupristin-dalfopristin, and vancomycin against the Michigan VRSA strain. Daptomycin and quinupristin-dalfopristin exhibited the greatest bacterial reductions, and all tested agents except vancomycin exhibited bactericidal activity against the VRSA.

引用

收藏

页码：3960 / 3963

页数：4

相关论文

共 28 条

[1] In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model [J].

Akins, RL ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1925-1929

[2] Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].

Akins, RL ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459

[3] DAPTOMYCIN DISRUPTS MEMBRANE-POTENTIAL IN GROWING STAPHYLOCOCCUS-AUREUS [J].

ALBORN, WE ;

ALLEN, NE ;

PRESTON, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2282-2287

[4] In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model [J].

Allen, GP ;

Cha, R ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2606-2612

[5]

[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902

[6]

[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565

[7] Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis [J].

Berthaud, N ;

Huet, Y ;

Diallo, N ;

Desnottes, JF .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :93-98

[8] INVITRO MODEL FOR SIMULTANEOUS SIMULATION OF THE SERUM KINETICS OF 2 DRUGS WITH DIFFERENT HALF-LIVES [J].

BLASER, J .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :125-130

[9] In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin [J].

Bouanchaud, DH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :15-21

[10] QUINUPRISTIN/DALFOPRISTIN (RP-59500) - A NEW STREPTOGRAMIN ANTIBIOTIC [J].

CHANT, C ;

RYBAK, MJ .

ANNALS OF PHARMACOTHERAPY, 1995, 29 (10) :1022-1027